My interview with Jimmy Moore should be up on the day that this post becomes available. (I usually write my posts on weekends and schedule them for release at the beginning of the following weeks.) So the time is opportune for me to try to aswer this question: What is a good low carbohydrate diet?
For me, and many people I know, the answer is: a low calorie one. What this means, in simple terms, is that a good low carbohydrate diet is one with plenty of seafood and organ meats in it, and also plenty of veggies. These are low carbohydrate foods that are also naturally low in calories. Conversely, a low carbohydrate diet of mostly beef and eggs would be a high calorie one.
Seafood and organ meats provide essential fatty acids and are typically packed with nutrients. Because of that, they tend to be satiating. In fact, certain organ meats, such as beef liver, are so packed with nutrients that it is a good idea to limit their consumption. I suggest eating beef liver once or twice a week only. As for seafood, it seems like a good idea to me to get half of one’s protein from them.
Does this mean that the calories-in-calories-out idea is correct? No, and there is no need to resort to complicated and somewhat questionable feedback-loop arguments to prove that calories-in-calories-out is wrong. Just consider this hypothetical scenario; a thought experiment. Take two men, one 25 years of age and the other 65, both with the same weight. Put them on the same exact diet, on the same exact weight training regime, and keep everything else the same.
What will happen? Typically the 65-year-old will put on more body fat than the 25-year-old, and the latter will put on more lean body mass. This will happen in spite of the same exact calories-in-calories-out profile. Why? Because their hormonal mixes are different. The 65-year-old will typically have lower levels of circulating growth hormone and testosterone, both of which significantly affect body composition.
As you can see, it is not all about insulin, as has been argued many times before. In fact, average and/or fasting insulin may be the same for the 65- and 25-year-old men. And, still, the 65-year-old will have trouble keeping his body fat low and gaining muscle. There are other hormones involved, such as leptin and adiponectin, and probably several that we don’t know about yet.
A low carbohydrate diet appears to be ideal for many people, whether that is due to a particular health condition (e.g., diabetes) or simply due to a genetic makeup that favors this type of diet. By adopting a low carbohydrate diet with plenty of seafood, organ meats, and veggies, you will make it a low calorie diet. If that leads to a calorie deficit that is too large, you can always add a bit more of fat to it. For example, by cooking fish with butter and adding bacon to beef liver.
One scenario where I don’t see the above working well is if you are a competitive athlete who depletes a significant amount of muscle glycogen on a daily basis – e.g., 250 g or more. In this case, it will be very difficult to replenish glycogen only with protein, so the person will need more carbohydrates. He or she would need a protein intake in excess of 500 g per day for replenishing 250 g of glycogen only with protein.
Showing posts with label growth hormone. Show all posts
Showing posts with label growth hormone. Show all posts
Monday, June 6, 2011
Monday, May 2, 2011
Strength training plus fasting regularly, and becoming diabetic!? No, it is just compensatory adaptation at work
One common outcome of doing glycogen-depleting exercise (e.g., strength training, sprinting) in combination with intermittent fasting is an increase in growth hormone (GH) levels. See this post for a graph showing the acute effect on GH levels of glycogen-depleting exercise. This effect applies to both men and women, and is generally healthy, leading to improvements in mood and many health markers.
It is a bit like GH therapy, with GH being “administered” to you by your own body. Both glycogen-depleting exercise and intermittent fasting increase GH levels; apparently they have an additive effect when done together.
Still, a complaint that one sees a lot from people who have been doing glycogen-depleting exercise and intermittent fasting for a while is that their fasting blood glucose levels go up. This is particularly true for obese folks (after they lose body fat), as obesity tends to be associated with low GH levels, although it is not restricted to the obese. In fact, many people decide to stop what they were doing because they think that they are becoming insulin resistant and on their way to developing type 2 diabetes. And, surely enough, when they stop, their blood glucose levels go down.
Guess what? If your blood glucose levels are going up quite a bit in response to glycogen-depleting exercise and intermittent fasting, maybe you are one of the lucky folks who are very effective at increasing their GH levels. The blood glucose increase effect is temporary, although it can last months, and is indeed caused by insulin resistance. An HbA1c test should also show an increase in hemoglobin glycation.
Over time, however, you will very likely become more insulin sensitive. What is happening is compensatory adaptation, with different short-term and long-term responses. In the short term, your body is trying to become a more efficient fat-burning machine, and GH is involved in this adaptation. But in the short term, GH leads to insulin resistance, probably via actions on muscle and fat cells. This gradually improves in the long term, possibly through a concomitant increase in liver insulin sensitivity and glycogen storage capacity.
This is somewhat similar to the response to GH therapy.
The figure below is from Johannsson et al. (1997). It shows what happened in terms of glucose metabolism when a group of obese men were administered recombinant GH for 9 months. The participants were aged 48–66, and were given in daily doses the equivalent to what would be needed to bring their GH levels to approximately what they were at age 20. For glucose, 5 mmol is about 90 mg, 5.5 is about 99, and 6 is about 108. GDR is glucose disposal rate; a measure of how quickly glucose is cleared from the blood.
As you can see, insulin sensitivity initially goes down for the GH group, and fasting blood glucose goes up quite a lot. But after 9 months the GH group has better insulin sensitivity. Their GDR is the same as in the placebo group, but with lower circulating insulin. The folks in the GH group also have significantly less body fat, and have better health markers, than those who took the placebo.
There is such a thing as sudden-onset type 2-like diabetes, but it is very rare (see Michael’s blog). Usually type 2 diabetes “telegraphs” its arrival through gradually increasing fasting blood glucose and HbA1c. However, those normally come together with other things, notably a decrease in HDL cholesterol and an increase in fasting triglycerides. Folks who do glycogen-depleting exercise and intermittent fasting tend to see the opposite – an increase in HDL cholesterol and a decrease in triglycerides.
So, if you are doing things that have the potential to increase your GH levels, a standard lipid panel can help you try to figure out whether insulin resistance is benign or not, if it happens.
By the way, GH and cortisol levels are correlated, which is often why some associate responses to glycogen-depleting exercise and intermittent fasting with esoteric nonsense that has no basis in scientific research like “adrenal fatigue”. Cortisol levels are meant to go up and down, but they should not go up and stay up while you are sitting down.
Avoid chronic stress, and keep on doing glycogen-depleting exercise and intermittent fasting; there is overwhelming scientific evidence that these things are good for you.
It is a bit like GH therapy, with GH being “administered” to you by your own body. Both glycogen-depleting exercise and intermittent fasting increase GH levels; apparently they have an additive effect when done together.
Still, a complaint that one sees a lot from people who have been doing glycogen-depleting exercise and intermittent fasting for a while is that their fasting blood glucose levels go up. This is particularly true for obese folks (after they lose body fat), as obesity tends to be associated with low GH levels, although it is not restricted to the obese. In fact, many people decide to stop what they were doing because they think that they are becoming insulin resistant and on their way to developing type 2 diabetes. And, surely enough, when they stop, their blood glucose levels go down.
Guess what? If your blood glucose levels are going up quite a bit in response to glycogen-depleting exercise and intermittent fasting, maybe you are one of the lucky folks who are very effective at increasing their GH levels. The blood glucose increase effect is temporary, although it can last months, and is indeed caused by insulin resistance. An HbA1c test should also show an increase in hemoglobin glycation.
Over time, however, you will very likely become more insulin sensitive. What is happening is compensatory adaptation, with different short-term and long-term responses. In the short term, your body is trying to become a more efficient fat-burning machine, and GH is involved in this adaptation. But in the short term, GH leads to insulin resistance, probably via actions on muscle and fat cells. This gradually improves in the long term, possibly through a concomitant increase in liver insulin sensitivity and glycogen storage capacity.
This is somewhat similar to the response to GH therapy.
The figure below is from Johannsson et al. (1997). It shows what happened in terms of glucose metabolism when a group of obese men were administered recombinant GH for 9 months. The participants were aged 48–66, and were given in daily doses the equivalent to what would be needed to bring their GH levels to approximately what they were at age 20. For glucose, 5 mmol is about 90 mg, 5.5 is about 99, and 6 is about 108. GDR is glucose disposal rate; a measure of how quickly glucose is cleared from the blood.
As you can see, insulin sensitivity initially goes down for the GH group, and fasting blood glucose goes up quite a lot. But after 9 months the GH group has better insulin sensitivity. Their GDR is the same as in the placebo group, but with lower circulating insulin. The folks in the GH group also have significantly less body fat, and have better health markers, than those who took the placebo.
There is such a thing as sudden-onset type 2-like diabetes, but it is very rare (see Michael’s blog). Usually type 2 diabetes “telegraphs” its arrival through gradually increasing fasting blood glucose and HbA1c. However, those normally come together with other things, notably a decrease in HDL cholesterol and an increase in fasting triglycerides. Folks who do glycogen-depleting exercise and intermittent fasting tend to see the opposite – an increase in HDL cholesterol and a decrease in triglycerides.
So, if you are doing things that have the potential to increase your GH levels, a standard lipid panel can help you try to figure out whether insulin resistance is benign or not, if it happens.
By the way, GH and cortisol levels are correlated, which is often why some associate responses to glycogen-depleting exercise and intermittent fasting with esoteric nonsense that has no basis in scientific research like “adrenal fatigue”. Cortisol levels are meant to go up and down, but they should not go up and stay up while you are sitting down.
Avoid chronic stress, and keep on doing glycogen-depleting exercise and intermittent fasting; there is overwhelming scientific evidence that these things are good for you.
Sunday, August 1, 2010
Growth hormone, insulin resistance, body fat accumulation, and glycogen depletion: Making sense of a mysterious hormone replacement therapy outcome
Hormone replacement therapies are prescribed in some cases, for medical reasons. They usually carry some risks. The risks come in part from the body down-regulating its own production of hormones when hormones are taken orally or injected. This could be seen as a form of compensatory adaptation, as the body tries to protect itself from abnormally high hormone levels.
More often than not the down-regulation can be reversed by interrupting the therapy. In some cases, the down-regulation becomes permanent, leading to significant health deterioration over the long run. One can seriously regret having started the hormone replacement therapy in the first place. The same is true (if not more) for hormone supplementation for performance enhancement, where normal hormone secretion levels are increased to enhance (mostly) athletic performance.
Rosenfalck and colleagues (1999) conducted an interesting study linking growth hormone (GH) replacement therapy with insulin resistance. Their conclusions are not very controversial. What I find interesting is what their data analysis unveiled and was not included in their conclusions. Also, they explain their main findings by claiming that there was a deterioration of beta cell function. (Beta cells are located in the pancreas, and secrete insulin.) While they may be correct, their explanation is not very plausible, as you will see below.
Let us take a quick look at what past research says about GH therapy and insulin resistance. One frequent finding is a significant but temporary impairment of insulin sensitivity, which usually normalizes after a period of a few months (e.g., 6 months). Another not so frequent finding is a significant and permanent impairment of insulin sensitivity; this is not as frequent in healthy individuals.
The researchers did a good job at reviewing this literature, and concluded that in many cases GH therapy is not worth the risk. They also studied 24 GH-deficient adults (18 males and 6 females). All of them had known pituitary pathology, which caused the low GH levels. The participants were randomly assigned to two groups. One received 4 months treatment with biosynthetic GH daily (n=13); the other received a placebo (n=11).
The table below (click on it to enlarge) shows various measures before and after treatment. Note the significant reduction in abdominal fat mass in the GH group. Also note that, prior to the treatment, the GH group folks (who were GH-deficient) were overall much heavier and much fatter, particular at the abdominal area, than the folks in the placebo (or control) group.
From the measures above one could say that the treatment was a success. But the researchers point out that it was not, because insulin sensitivity was significantly impaired. They show some graphs (below), and that is where things get really interesting, but not in the way intended by the researchers.
On the figure above, the graphs on the left refer to the placebo group, and on the right to the GH group. The solid lines reflect pre-treatment numbers and dotted lines post-treatment numbers. Indeed, GH therapy is making the GH-deficient folks significantly more insulin resistant.
But look carefully. The GH folks are more insulin sensitive than the controls prior to the treatment, even though they are much fatter, particularly in terms of abdominal fat. The glucose response is significantly lower for the GH-deficient folks, and that is not due to them secreting more insulin. The insulin response is also significantly lower. This is confirmed by glucose and insulin “area under the curve” measures provided by the researchers.
In fact, after treatment both groups seem to have generally the same insulin and glucose responses. This means that the GH treatment made insulin-sensitive folks a bit more like their normal counterparts in the placebo group. But obviously the change for the worse occurred only in the GH group, which is what the researchers concluded.
Now to the really interesting question, at least in my mind: What could have improved insulin sensitivity in the GH-deficient group prior to the treatment?
The GH-deficient folks had more body fat, particularly around the abdominal area. High serum GH is usually associated with low body fat, particularly around the abdominal area, because high GH folks burn it easily. So, looking at it from a different perspective, the GH-deficient folks seem to have been more effective at making body fat, and less effective at burning it.
Often we talk about insulin sensitivity as though there was only one type. But there is more than one type of insulin sensitivity. Insulin signals to the liver to take up glucose from the blood and turn it into glycogen or fat. Insulin also signals to body fat tissue to take up glucose from the blood and make fat with it. (GLUT 4 is an insulin-sensitive glucose transporter present in both fat and muscle cells.)
Therefore, it is reasonable to assume that folks with fat cells that are particularly insulin-sensitive would tend to make body fat quite easily based on glucose. While this is a type of insulin sensitivity that most people probably do not like to have, it may play an important role in reducing blood glucose levels under certain conditions. This appears to be true in the short term. Down the road, having very insulin-sensitive fat cells seems to lead to obesity, the metabolic syndrome, and diabetes.
In fact, in individuals without pituitary pathology, increased insulin sensitivity in fat cells could be a compensatory adaptation in response to a possible decrease in liver and muscle glucose uptake. Lack of exercise will shift the burden of glucose clearance to tissues other than liver and muscle, because with glycogen stores full both liver and muscle will usually take up much less blood glucose than they would otherwise.
I am speculating here, but I think that in individuals without pituitary pathology, an involuntary decrease in endogenous GH secretion may actually be at the core of this compensatory adaptation mechanism. In these individuals, low GH levels may be an outcome, not a cause of problems. This would explain two apparently contradictory findings: (a) GH levels drop dramatically in the 40s, particularly for men; and (b) several people in their 50s and 60s, including men, have much higher levels of circulating GH than people in their 40s, and even than much younger folks.
Vigorous exercise increases blood glucose uptake, inside and outside the exercise window; this is an almost universal effect among humans. Exercise depletes muscle and liver glycogen. (Fasting and low-carbohydrate dieting alone deplete liver, but not muscle, glycogen.) As glycogen stores become depleted, the activity of glycogen synthase (an enzyme involved in the conversion of glucose to glycogen) increases acutely. This activity remains elevated for several days in muscle tissue; the liver replenishes its glycogen in a matter of hours. With glycogen synthase activity elevated, glucose is quickly used to replenish glycogen stores, and not to make fat.
Depleting glycogen stores on a regular basis (e.g., once every few days) may over time reverse the adaptations that made fat cells particularly insulin-sensitive in the first place. Those adaptations become a protection that is not only no longer needed but also detrimental to health, since they lead to obesity. This could be the reason why many people initially find it difficult to lower their body fat set point, but once they lose body fat and stay lean for a while, they seem to become able to maintain their leanness without much effort.
Well, perhaps glycogen-depleting exercise is more important than many people think. It can help make you thin, but through a circuitous path.
And, incidentally, glycogen-depleting exercise causes a temporary but dramatic spike in GH secretion. This natural increase in GH secretion does not seem to be associated with any significant impairment in overall insulin sensitivity, even though glycogen-depleting exercise increases blood glucose levels a lot during the exercise window. This is a temporary and physiological, not pathological, phenomenon.
Reference:
Rosenfalck A.M., Fisker, S., Hilsted, J., Dinesen, B., Vølund, A., Jørgensen, J.O., Christiansen, J.S., & Madsbad, S. (1999). The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. Growth Hormone & IGF Research, 9(2), 96–105.
More often than not the down-regulation can be reversed by interrupting the therapy. In some cases, the down-regulation becomes permanent, leading to significant health deterioration over the long run. One can seriously regret having started the hormone replacement therapy in the first place. The same is true (if not more) for hormone supplementation for performance enhancement, where normal hormone secretion levels are increased to enhance (mostly) athletic performance.
Rosenfalck and colleagues (1999) conducted an interesting study linking growth hormone (GH) replacement therapy with insulin resistance. Their conclusions are not very controversial. What I find interesting is what their data analysis unveiled and was not included in their conclusions. Also, they explain their main findings by claiming that there was a deterioration of beta cell function. (Beta cells are located in the pancreas, and secrete insulin.) While they may be correct, their explanation is not very plausible, as you will see below.
Let us take a quick look at what past research says about GH therapy and insulin resistance. One frequent finding is a significant but temporary impairment of insulin sensitivity, which usually normalizes after a period of a few months (e.g., 6 months). Another not so frequent finding is a significant and permanent impairment of insulin sensitivity; this is not as frequent in healthy individuals.
The researchers did a good job at reviewing this literature, and concluded that in many cases GH therapy is not worth the risk. They also studied 24 GH-deficient adults (18 males and 6 females). All of them had known pituitary pathology, which caused the low GH levels. The participants were randomly assigned to two groups. One received 4 months treatment with biosynthetic GH daily (n=13); the other received a placebo (n=11).
The table below (click on it to enlarge) shows various measures before and after treatment. Note the significant reduction in abdominal fat mass in the GH group. Also note that, prior to the treatment, the GH group folks (who were GH-deficient) were overall much heavier and much fatter, particular at the abdominal area, than the folks in the placebo (or control) group.
From the measures above one could say that the treatment was a success. But the researchers point out that it was not, because insulin sensitivity was significantly impaired. They show some graphs (below), and that is where things get really interesting, but not in the way intended by the researchers.
On the figure above, the graphs on the left refer to the placebo group, and on the right to the GH group. The solid lines reflect pre-treatment numbers and dotted lines post-treatment numbers. Indeed, GH therapy is making the GH-deficient folks significantly more insulin resistant.
But look carefully. The GH folks are more insulin sensitive than the controls prior to the treatment, even though they are much fatter, particularly in terms of abdominal fat. The glucose response is significantly lower for the GH-deficient folks, and that is not due to them secreting more insulin. The insulin response is also significantly lower. This is confirmed by glucose and insulin “area under the curve” measures provided by the researchers.
In fact, after treatment both groups seem to have generally the same insulin and glucose responses. This means that the GH treatment made insulin-sensitive folks a bit more like their normal counterparts in the placebo group. But obviously the change for the worse occurred only in the GH group, which is what the researchers concluded.
Now to the really interesting question, at least in my mind: What could have improved insulin sensitivity in the GH-deficient group prior to the treatment?
The GH-deficient folks had more body fat, particularly around the abdominal area. High serum GH is usually associated with low body fat, particularly around the abdominal area, because high GH folks burn it easily. So, looking at it from a different perspective, the GH-deficient folks seem to have been more effective at making body fat, and less effective at burning it.
Often we talk about insulin sensitivity as though there was only one type. But there is more than one type of insulin sensitivity. Insulin signals to the liver to take up glucose from the blood and turn it into glycogen or fat. Insulin also signals to body fat tissue to take up glucose from the blood and make fat with it. (GLUT 4 is an insulin-sensitive glucose transporter present in both fat and muscle cells.)
Therefore, it is reasonable to assume that folks with fat cells that are particularly insulin-sensitive would tend to make body fat quite easily based on glucose. While this is a type of insulin sensitivity that most people probably do not like to have, it may play an important role in reducing blood glucose levels under certain conditions. This appears to be true in the short term. Down the road, having very insulin-sensitive fat cells seems to lead to obesity, the metabolic syndrome, and diabetes.
In fact, in individuals without pituitary pathology, increased insulin sensitivity in fat cells could be a compensatory adaptation in response to a possible decrease in liver and muscle glucose uptake. Lack of exercise will shift the burden of glucose clearance to tissues other than liver and muscle, because with glycogen stores full both liver and muscle will usually take up much less blood glucose than they would otherwise.
I am speculating here, but I think that in individuals without pituitary pathology, an involuntary decrease in endogenous GH secretion may actually be at the core of this compensatory adaptation mechanism. In these individuals, low GH levels may be an outcome, not a cause of problems. This would explain two apparently contradictory findings: (a) GH levels drop dramatically in the 40s, particularly for men; and (b) several people in their 50s and 60s, including men, have much higher levels of circulating GH than people in their 40s, and even than much younger folks.
Vigorous exercise increases blood glucose uptake, inside and outside the exercise window; this is an almost universal effect among humans. Exercise depletes muscle and liver glycogen. (Fasting and low-carbohydrate dieting alone deplete liver, but not muscle, glycogen.) As glycogen stores become depleted, the activity of glycogen synthase (an enzyme involved in the conversion of glucose to glycogen) increases acutely. This activity remains elevated for several days in muscle tissue; the liver replenishes its glycogen in a matter of hours. With glycogen synthase activity elevated, glucose is quickly used to replenish glycogen stores, and not to make fat.
Depleting glycogen stores on a regular basis (e.g., once every few days) may over time reverse the adaptations that made fat cells particularly insulin-sensitive in the first place. Those adaptations become a protection that is not only no longer needed but also detrimental to health, since they lead to obesity. This could be the reason why many people initially find it difficult to lower their body fat set point, but once they lose body fat and stay lean for a while, they seem to become able to maintain their leanness without much effort.
Well, perhaps glycogen-depleting exercise is more important than many people think. It can help make you thin, but through a circuitous path.
And, incidentally, glycogen-depleting exercise causes a temporary but dramatic spike in GH secretion. This natural increase in GH secretion does not seem to be associated with any significant impairment in overall insulin sensitivity, even though glycogen-depleting exercise increases blood glucose levels a lot during the exercise window. This is a temporary and physiological, not pathological, phenomenon.
Reference:
Rosenfalck A.M., Fisker, S., Hilsted, J., Dinesen, B., Vølund, A., Jørgensen, J.O., Christiansen, J.S., & Madsbad, S. (1999). The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy. Growth Hormone & IGF Research, 9(2), 96–105.
Subscribe to:
Posts (Atom)